Form 4: Revolution Medicines Director Acquires Shares and Stock Options

Director Sushil Patel acquired 4,800 shares of common stock and 16,700 stock options in Revolution Medicines, Inc.

Summary

• On June 20, 2024, Sushil Patel, a director of Revolution Medicines, Inc., acquired 4,800 shares of common stock at $0.
• Following the transaction, Patel directly owns 20,500 shares of common stock, including 9,175 Restricted Stock Units.
• Patel also acquired 16,700 stock options with an exercise price of $37.54, exercisable starting June 20, 2024, and expiring on June 19, 2034.
• The stock options vest in full on the earlier of the first anniversary of June 20, 2024, or immediately prior to the Annual Meeting following the date of grant, subject to continued service.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction disclosure. The acquisition of shares and options could be interpreted as a positive sign, but it's not definitively indicative of significant positive or negative sentiment.

Positives

• The director's acquisition of shares and stock options could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the stock options is contingent on the director's continued service with the company.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when a company insider, such as a director, buys or sells the company's securities. It provides transparency to the market regarding insider transactions.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's increased investment in the company.

Key Dates